Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b

Dogwood Therapeutics, Inc.

Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).
Consideration: 382,034 common shares + 179.1878 Series A-2 Preferred shares (convert 1:10,000), representing 7.31% fully diluted.
Phase 1b CIPN study fully funded by NCI; patient enrollment projected first half 2026.
Halneuron Phase 2b ongoing (80 patients randomized); interim data from 90-100 patients expected December 2025.
Support agreements with Serpin, Tungsten, and Sealbond to vote for stockholder approval of preferred stock conversions.

item 1.01 item 5.03 item 3.02 item 3.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Dogwood Therapeutics, Inc.: Company filed a Certificate of Designation for Series A-2 Non-Voting Convertible Preferred Stock, establishing preferences, rights, and limitations including voting restrictions, dividend prohibition, conversion rights, and protective provisions (effective 2025-09-29).

Change: charter amendment
Effective: 2025-09-29

Exact text from the filing

On September 29, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A-2 Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Serpin Registration Rights Agreement referenced in Item 1.01 above.

View on SEC.gov

Browse all governance changes →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-094109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.